Patents Assigned to Mesoblast, Inc.
  • Publication number: 20160361362
    Abstract: The present disclosure provides methods of improving cerebral function or preventing loss of cerebral function and/or treating or preventing a movement disorder and/or regenerating cerebral neurons in a subject who has suffered a stroke, the method comprising administering to the subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Application
    Filed: August 11, 2014
    Publication date: December 15, 2016
    Applicants: CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC, MESOBLAST, INC.
    Inventors: Simon Andrea KOBLAR, Stan GRONTHOS, Agnieszka ARTHUR
  • Publication number: 20160361363
    Abstract: A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1bright cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Application
    Filed: February 26, 2016
    Publication date: December 15, 2016
    Applicant: Mesoblast, Inc.
    Inventors: Silviu Itescu, Michael David Schuster
  • Patent number: 9487756
    Abstract: The present invention provides a method of producing a reprogrammed cell, said method comprising exposing Stro-1+ multipotential cells and/or progeny cells thereof to one or more potency-determining factors under conditions sufficient to reprogram the cells. The present invention also provides cells produced by such a method and cells differentiated therefrom in addition to various uses of those cells.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: November 8, 2016
    Assignee: MESOBLAST, INC.
    Inventor: Silviu Itescu
  • Publication number: 20160317581
    Abstract: Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as STRO-1 and CD146/MUC18. The perivascular mesenchymal precursor cell is shown to induce neovascularisation and improvement in cardiac function. Suitable administration of preparations of the mesenchymal precursor cells are useful for treatment of cardiovascular diseases, cerebrovascular diseases and peripheral vascular diseases.
    Type: Application
    Filed: September 30, 2015
    Publication date: November 3, 2016
    Applicant: MESOBLAST, INC.
    Inventors: Stan Gronthos, Andrew Zannettino
  • Patent number: 9480713
    Abstract: The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1+ cells and/or progeny cells thereof and/or soluble factors derived therefrom. The method of the invention is useful for treating and/or preventing and/or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: November 1, 2016
    Assignee: MESOBLAST, INC.
    Inventors: Silviu Itescu, Ravi Krishnan
  • Publication number: 20160264683
    Abstract: The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.
    Type: Application
    Filed: May 27, 2016
    Publication date: September 15, 2016
    Applicant: Mesoblast, Inc.
    Inventors: Stan Gronthos, Andrew Christopher William Zannettino, John Paul Simmons
  • Patent number: 9415072
    Abstract: The present invention relates to a method of transplanting haematopoietic precursor cells into a subject in need thereof which involves culturing the haematopoietic precursor cells in the presence of a population of cells enriched for STRO-1bright cells. The method of the present invention is useful in the treatment of haematological disorders.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: August 16, 2016
    Assignee: MESOBLAST, INC.
    Inventors: Silviu Itescu, Michael David Schuster
  • Publication number: 20160199415
    Abstract: The present disclosure provides a method for treating or preventing a rheumatic disease, comprising administering a population of cells enriched for STRO-1+cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Application
    Filed: January 11, 2016
    Publication date: July 14, 2016
    Applicant: MESOBLAST, INC.
    Inventors: Peter Ghosh, Silviu Itescu
  • Patent number: 9388385
    Abstract: The present disclosure provides methods of treating or preventing obesity or causing weight loss or treating or preventing metabolic syndrome comprising administering to a subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: July 12, 2016
    Assignee: MESOBLAST, INC.
    Inventors: Ravi Krishnan, Silviu Itescu
  • Patent number: 9381216
    Abstract: This invention relates to a method for generating, repairing and/or maintaining connective tissue in a subject. In one embodiment, the invention relates to a method for generating, repairing and/or maintaining cartilage tissue in a subject. The present invention also relates to a method of treating and/or preventing a disease in a subject arising from degradation and inflammation of connective tissue.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: July 5, 2016
    Assignee: MESOBLAST, INC.
    Inventor: Peter Ghosh
  • Publication number: 20160175360
    Abstract: The present disclosure provides a method for treating or preventing endothelial dysfunction in a subject, the method comprising systemically administering to the subject a population of population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Application
    Filed: December 12, 2013
    Publication date: June 23, 2016
    Applicant: Mesoblast, Inc.
    Inventors: Wayne Gregory KIMPTON, Simon Reeves BAILEY, Silviu ITESCU, Peter GHOSH
  • Patent number: 9301978
    Abstract: A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1bright cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Grant
    Filed: July 4, 2011
    Date of Patent: April 5, 2016
    Assignee: MESOBLAST, INC.
    Inventors: Silviu Itescu, Michael David Schuster
  • Patent number: 9265796
    Abstract: The present disclosure provides a method for treating or preventing a rheumatic disease, comprising administering a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Grant
    Filed: July 4, 2012
    Date of Patent: February 23, 2016
    Assignee: MESOBLAST, INC.
    Inventors: Peter Ghosh, Silviu Itescu
  • Patent number: 9175267
    Abstract: Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as STRO-1 and CD146/MUC18. The perivascular mesenchymal precursor cell is shown to induce neovascularization and improvement in cardiac function. Suitable administration of preparations of the mesenchymal precursor cells are useful for treatment of cardiovascular diseases, cerebrovascular diseases and peripheral vascular diseases.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: November 3, 2015
    Assignee: MESOBLAST, INC.
    Inventors: Stan Gronthos, Andrew Zannettino
  • Publication number: 20150306146
    Abstract: The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an IgE-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Application
    Filed: December 12, 2013
    Publication date: October 29, 2015
    Applicant: MESOBLAST, INC.
    Inventors: Silviu ITESCU, Ravi KRISHNAN, Peter GHOSH
  • Publication number: 20150307608
    Abstract: The present invention relates to a monoclonal antibody designated STRO-4 which specifically binds human and ovine HSP-90beta and its use for enriching multipotential cells such as mesenchymal precursor cells (MPCs).
    Type: Application
    Filed: July 9, 2015
    Publication date: October 29, 2015
    Applicant: MESOBLAST, INC.
    Inventors: Stan Gronthos, Andrew Christopher William Zannettino
  • Patent number: 9169466
    Abstract: Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as STRO-1 and CD146/MUC18. The perivascular mesenchymal precursor cell is shown to induce neovascularization and improvement in cardiac function. Suitable administration of preparations of the mesenchymal precursor cells are useful for treatment of cardiovascular diseases, cerebrovascular diseases and peripheral vascular diseases.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: October 27, 2015
    Assignee: MESOBLAST, INC.
    Inventors: Stan Gronthos, Andrew Zannettino
  • Patent number: 9090678
    Abstract: The present invention relates to a monoclonal antibody designated STRO-4 which specifically binds human and ovine HSP-90beta and its use for enriching multipotential cells such a mesenchymal precursor cells (MPCs).
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: July 28, 2015
    Assignee: MESOBLAST, INC.
    Inventors: Stan Gronthos, Andrew Christopher Williem Zannettino
  • Publication number: 20150202232
    Abstract: The present invention relates to a method of transplanting haematopoietic precursor cells into a subject in need thereof which involves culturing the haematopoietic precursor cells in the presence of a population of cells enriched for STRO-1bright cells. The method of the present invention is useful in the treatment of haematological disorders.
    Type: Application
    Filed: September 3, 2014
    Publication date: July 23, 2015
    Applicant: MESOBLAST, INC.
    Inventors: Silviu Itescu, Michael David Schuster
  • Publication number: 20150064148
    Abstract: The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1+ cells and/or progeny cells thereof and/or soluble factors derived therefrom. The method of the invention is useful for treating and/or preventing and/or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Applicant: MESOBLAST, INC.
    Inventors: Silviu Itescu, Ravi Krishnan